Prognostic factors associated with time to hCG remission in patients with low-risk postmolar gestational trophoblastic neoplasia.

[1]  R. Verheijen,et al.  Fatal cases of gestational trophoblastic neoplasia over four decades in the Netherlands: a retrospective cohort study , 2012, BJOG : an international journal of obstetrics and gynaecology.

[2]  N. Sebire,et al.  Treatment outcomes for 618 women with gestational trophoblastic tumours following a molar pregnancy at the Charing Cross Hospital, 2000–2009 , 2012, British Journal of Cancer.

[3]  A. Rademaker,et al.  Treatment of nonmetastatic and metastatic low-risk gestational trophoblastic neoplasia: factors associated with resistance to single-agent methotrexate chemotherapy. , 2012, Gynecologic oncology.

[4]  R. Osborne,et al.  Gestational trophoblastic neoplasia. , 2012, Obstetrics and gynecology clinics of North America.

[5]  R. Berkowitz,et al.  A cost analysis of first-line chemotherapy for low-risk gestational trophoblastic neoplasia. , 2012, The Journal of reproductive medicine.

[6]  U. Surti,et al.  The genetics of gestational trophoblastic disease: a rare complication of pregnancy. , 2012, Cancer genetics.

[7]  R. Berkowitz,et al.  Current management of gestational trophoblastic neoplasia. , 2012, Hematology/oncology clinics of North America.

[8]  D. Provencher,et al.  Phase III trial of weekly methotrexate or pulsed dactinomycin for low-risk gestational trophoblastic neoplasia: a gynecologic oncology group study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  J. Lurain.  Gestational trophoblastic disease II: classification and management of gestational trophoblastic neoplasia. , 2011, American journal of obstetrics and gynecology.

[10]  R. Berkowitz,et al.  Low-risk gestational trophoblastic neoplasia and methotrexate resistance: predictors of response to treatment with actinomycin D and need for combination chemotherapy. , 2010, The Journal of reproductive medicine.

[11]  M. Seckl,et al.  The management and outcome of women with post-hydatidiform mole ‘low-risk’ gestational trophoblastic neoplasia, but hCG levels in excess of 100 000 IU l−1 , 2010, British Journal of Cancer.

[12]  S. Wilailak,et al.  Actinomycin D Versus Methotrexate-Folinic Acid as the Treatment of Stage I, Low-Risk Gestational Trophoblastic Neoplasia: A Randomized Controlled Trial , 2009, International Journal of Gynecologic Cancer.

[13]  G. Chalouhi,et al.  Methotrexate for 2000 FIGO low-risk gestational trophoblastic neoplasia patients: efficacy and toxicity. , 2009, American journal of obstetrics and gynecology.

[14]  R. Berkowitz,et al.  Evaluating methotrexate treatment in patients with low-risk postmolar gestational trophoblastic neoplasia. , 2009, Gynecologic oncology.

[15]  A. Rademaker,et al.  Gestational Trophoblastic Neoplasia: Treatment Outcomes , 2008, Obstetrics and gynecology.

[16]  R. Berkowitz,et al.  Gestational Trophoblastic Disease , 1998, Clinical obstetrics and gynecology.

[17]  R. Berkowitz,et al.  Clinical characteristics of persistent gestational trophoblastic neoplasia after partial hydatidiform molar pregnancy. , 2006, The Journal of reproductive medicine.

[18]  C. Sweep,et al.  The curative effect of a second curettage in persistent trophoblastic disease: a retrospective cohort survey. , 2005, Gynecologic oncology.

[19]  P. Hanjani,et al.  Comparison of pulse methotrexate and pulse dactinomycin in the treatment of low‐risk gestational trophoblastic neoplasia , 2005, The Australian & New Zealand journal of obstetrics & gynaecology.

[20]  R. Coleman,et al.  The role of repeat uterine evacuation in the management of persistent gestational trophoblastic disease. , 2004, Gynecologic oncology.

[21]  R. Berkowitz,et al.  Methotrexate infusion and folinic acid as primary therapy for nonmetastatic and low-risk metastatic gestational trophoblastic tumors. 15 years of experience. , 2002, The Journal of reproductive medicine.

[22]  I. McNeish,et al.  Doppler ultrasonography of the uterine artery and the response to chemotherapy in patients with gestational trophoblastic tumors. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[23]  G. Rustin,et al.  Low-risk persistent gestational trophoblastic disease: outcome after initial treatment with low-dose methotrexate and folinic acid from 1992 to 2000. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  E. Kohorn.  The new FIGO 2000 staging and risk factor scoring system for gestational trophoblastic disease: Description and critical assessment , 2000, International Journal of Gynecologic Cancer.

[25]  M. Seckl,et al.  Choriocarcinoma and partial hydatidiform moles , 2000, The Lancet.

[26]  M. Hoffman,et al.  A single institution experience with weekly intramuscular methotrexate for nonmetastatic gestational trophoblastic disease. , 1996, Gynecologic oncology.

[27]  R. Berkowitz,et al.  The psychological, social, and sexual consequences of gestational trophoblastic disease. , 1992, Gynecologic oncology.

[28]  M. Rettenmaier,et al.  Rapid escalation of weekly intramuscular methotrexate for nonmetastatic gestational trophoblastic disease: a Gynecologic Oncology Group study. , 1990, Gynecologic oncology.

[29]  R. Berkowitz,et al.  Ten years' experience with methotrexate and folinic acid as primary therapy for gestational trophoblastic disease , 1986 .

[30]  R. Berkowitz,et al.  Psychological and social impact of gestational trophoblastic neoplasia. , 1980, Journal of reproductive medicine.